Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$10.4MCash on Hand
11.5mo Cash Runway
Follow RNXT by emailGet an email when RNXT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RNXT, unsubscribe in one click. Privacy
📣 What RNXT Says Is Next
second half of 2027 · “RenovoRx completed enrollment in the Phase III TIGeR-PaC clinical trial in August 2026, and anticipates the initial topline data in the second half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
second half of 2027 · “RenovoRx anticipates initial top-line data in the second half of 2027 and expects the data readout to support and potentially expand current clinical adoption of TAMP by providing more rigorous evidence on tolerability and reduced side effects.”
Company press release, Nov 5, 2026 · SEC filing
late 2027 · “RenovoRx anticipates full enrollment in the TIGeR-PaC trial in the very near term and final data readout in mid to late 2027.”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings RenovoRx reported Q3 2026 revenue of $1.07 million, up from $266,000 a year earlier, with 26 active commercial cancer center customers and maintained 2026 revenue guidance of $3.75M to $4.25M. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 20, 2026 ·
Listing Nasdaq confirmed RenovoRx regained compliance with the minimum bid price requirement after its common stock closed at or above $1.00 for ten consecutive business days from August 6 through August 19, 2026, and considers the matter closed. Form 8-K · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 revenue of $909,000, up about 61% from Q1 and 115% from Q2 2025, with 21 active commercial cancer center customers and full-year 2026 revenue guidance raised to $3.75M to $4.25M. Phase III TIGeR-PaC enrollment is complete, with topline data expected in the second half of 2027. Form 8-K/A · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 12, 2026 ·
Earnings Reported Q2 2026 revenue of $909,000, up about 61% from Q1 and 115% from Q2 2025, and raised full-year 2026 revenue guidance to $3.75M to $4.25M. Active commercial cancer center customers reached 21. Phase III TIGeR-PaC trial completed enrollment, with topline data expected in 2H 2027. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2027 · Phase 3 · Active Trial · Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Registry primary completion date, not a results date
Sep 2029 · N/A · Recruiting · PumaRx Registry Trial Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not RNXT's own candidates): Gemcitabine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RNXT holds $10.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.7M/quarter from operations,
an estimated runway of 11.5 months at that rate (BioRadar estimate, not company guidance).
Share count 48,250,592 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RNXT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNXT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.